Effect of treatment with mometasone furoate/formoterol combination on rescue medication use

C. LaForce, E. Meltzer, R. Nathan, A. Nayak, H. Nolte, D. Pearlman (Raleigh, San Diego, Colorado Springs, Normal, Kenilworth, Denver, United States Of America)

Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Session: Combination therapy in asthma and COPD
Session type: Thematic Poster Session
Number: 1213
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. LaForce, E. Meltzer, R. Nathan, A. Nayak, H. Nolte, D. Pearlman (Raleigh, San Diego, Colorado Springs, Normal, Kenilworth, Denver, United States Of America). Effect of treatment with mometasone furoate/formoterol combination on rescue medication use. Eur Respir J 2010; 36: Suppl. 54, 1213

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy and safety of medium and high doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010


Fluticasone propionate/formoterol fumarate combination therapy has an efficacy and safety profile similar to that of its individual components administered concurrently in the treatment of asthma
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Efficacy and safety of combined mometasone furoate/formoterol 200/10μg in persistent asthmatics
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010


Efficacy and safety of combined mometasone furoate/formoterol 100/10μg twice daily in subjects with asthma inadequately controlled on low-dose inhaled corticosteroids
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010


Fluticasone propionate/formoterol fumarate combination therapy has comparable efficacy to its individual components administered concurrently
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011

Fluticasone propionate/formoterol fumarate combination therapy is as effective as fluticasone propionate/salmeterol xinafoate, but has a more rapid onset of action in the treatment of asthma
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Once-daily versus twice-daily administration of mometasone furoate dry powder inhaler (MF-DPI) improves lung function in children with asthma previously maintained on inhaled corticosteroids (ICS)
Source: Eur Respir J 2004; 24: Suppl. 48, 164s
Year: 2004

Effect of mometasone furoate/formoterol combination therapy on nocturnal awakenings in subjects with persistent asthma
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010


Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011

Effects of one year of treatment with mometasone furoate metered dose inhaler (MF-MDI) on growth in children with asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 378s
Year: 2004

Fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy has comparable efficacy to fluticasone propionate/salmeterol xinafoate (FLUT/SAL) in paediatric patients with asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011


Initial maintenance therapy with fluticasone propionate/ salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

Fluticasone propionate/formoterol fumarate combination therapy is more effective than fluticasone propionate alone in the treatment of asthma
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

LATE-BREAKING ABSTRACT: ENERGITO: Efficacy and safety of once-daily combined tiotropium + olodaterol versus twice-daily combined fluticasone propionate + salmeterol
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015


Fluticasone propionate/formoterol fumarate combination therapy has superior efficacy to both fluticasone and formoterol alone
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma
Source: Eur Respir J 2007; 29: 682-689
Year: 2007



Effects of budesonide/formoterol combination therapy versus budesonide on airway dimensions in asthma
Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases
Year: 2012

Short-acting bronchodilator and oral steroid use in asthma patients prescribed either concurrent beclometasone and salmeterol or combined salmeterol/fluticasone
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004

Effectiveness and safety of fluticasone propionate/salmeterol 250/50mcg administered once daily to patients with persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004

Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 50s
Year: 2003